Login to Your Account



Funds are Stretched Thin

AMT Prepares for Glybera's Phase III Extension Study

By Nuala Moran


Wednesday, August 31, 2011
LONDON – Amsterdam Molecular Therapeutics (AMT) NV is now poised to begin the Phase III extension study of Glybera, its gene therapy treatment for lipoprotein lipase deficiency, and is paring back expenditure as it awaits a response from the European Medicines Agency (EMA) to its request for a re-examination of the Glybera file. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription